Deep Genomics
ON - TorontoBiotechnology
Focus: Deep Genomics is an AI-driven biotechnology company specializing in oligonucleotide therapy discovery, leveraging machine learning to accelerate drug development. The company operates at a mid-cap biotech scale (51-200 employees) with public market status and focused therapeutic expertise in musculoskeletal diseases.
Profile data last refreshed 12h ago · AI intelligence enriched 2w ago
Funding Stage
PUBLIC
Employees
51-200
Open Jobs
1-2 this month
Stable — net -2 jobs in 30d
1 added, 3 removed. Backfill posture.
Should You Work at Deep Genomics?
AI assessmentDeep Genomics offers a high-risk, high-impact opportunity for scientists and engineers committed to AI-driven drug discovery, but prospective hires should clarify clinical timeline and funding durability before committing.
Why Work Here
- Opportunity to work at the intersection of AI and genomics—a high-growth market segment with public validation and structural tailwinds
Data completeness
3/9 — Basic
Company HealthSolid
Pipeline
Early-stage
0 total
LOE Risk
Protected
No near-term cliffs
Hiring
Slowing
Jobs decreasing
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Deep Genomics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.